{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:26:24Z","timestamp":1789233984672,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Roche Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.07.138","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T20:22:34Z","timestamp":1540239754000},"page":"210-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers"],"prefix":"10.1016","volume":"104","author":[{"given":"Carin A.T.C.","family":"Lunenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Henricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dreussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke P.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Meulendijks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.ejca.2018.07.138_bib1","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0305-7372(10)70020-7","article-title":"Update on capecitabine alone and in combination regimens in colorectal cancer patients","volume":"36","author":"Silvestris","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2018.07.138_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00414-2","article-title":"Rational development of capecitabine","volume":"38","author":"Venturini","year":"2002","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.138_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.138_bib4","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/jama.1990.03450110090034","article-title":"NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer","volume":"264","year":"1990","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.ejca.2018.07.138_bib5","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/0959-8049(93)90012-5","article-title":"Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group","volume":"29a","author":"Bosset","year":"1993","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.138_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncponc0714","article-title":"The concurrent chemoradiation paradigm--general principles","volume":"4","author":"Seiwert","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.07.138_bib7","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2018.07.138_bib8","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1200\/JCO.2002.02.049","article-title":"Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer","volume":"20","author":"Dunst","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.07.138_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bjc.6602106","article-title":"A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer","volume":"91","author":"Ngan","year":"2004","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2018.07.138_bib10","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2018.07.138_bib11","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2018.07.138_bib12","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.138_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2006.05.063","article-title":"Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer","volume":"66","author":"Krishnan","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.ejca.2018.07.138_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00066-008-1751-4","article-title":"Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial","volume":"184","author":"Dunst","year":"2008","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"10.1016\/j.ejca.2018.07.138_bib15","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.07.138_bib16","series-title":"Fluorouracil\/capecitabine DPD gene activity score and guidelines","author":"KNMP. Royal Dutch Society for the Advancement of Pharmacy","year":"2015"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.138_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ejca.2018.07.138_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/pgs.15.70","article-title":"Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score","volume":"16","author":"Henricks","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.138_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.138_bib20","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v3.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. [Accessed 23 April 2018]."},{"key":"10.1016\/j.ejca.2018.07.138_bib21","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v4.03. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. [Accessed 23 April 2018]."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918311237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918311237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T08:21:04Z","timestamp":1549009264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918311237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":21,"alternative-id":["S0959804918311237"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.138","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}